{"filing":{"accession_number":"0001437749-26-018098","cik":"0000719135","ticker":"APYX","company_name":"Apyx Medical Corp","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"apyx20260521_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/719135/000143774926018098/apyx20260521_8k.htm"},"events":[{"id":9501,"run_id":8334,"accession_number":"0001437749-26-018098","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"Apyx Medical announced publication of clinical data in a peer-reviewed journal (Aesthetic Surgery Journal Open Forum) demonstrating efficacy for cellulite and skin laxity treatment. While this is a positive clinical validation event relevant to the company's product portfolio and market positioning, it does not fit neatly into the more specific event categories (not earnings, M\u0026A, litigation, impairment, etc.). The disclosure is material to investors assessing the company's clinical evidence base and competitive standing in aesthetic medicine, but the ambiguity about whether this constitutes a \"material\" event versus routine clinical publication reporting warrants moderate confidence.","company_name":"Apyx Medical Corp","ticker":"APYX","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1155,"accession_number":"0001437749-26-018098","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"Apyx Medical announced publication of clinical data in a peer-reviewed journal (Aesthetic Surgery Journal Open Forum) demonstrating efficacy for cellulite and skin laxity treatment. While this is a positive clinical validation event relevant to the company's product portfolio and market positioning, it does not fit neatly into the more specific event categories (not earnings, M\u0026A, litigation, impairment, etc.). The disclosure is material to investors assessing the company's clinical evidence base and competitive standing in aesthetic medicine, but the ambiguity about whether this constitutes a \"material\" event versus routine clinical publication reporting warrants moderate confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:00:20.648554+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1155,"accession_number":"0001437749-26-018098","item_number":"8.01","item_title":"Other Events","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"Apyx Medical announced publication of clinical data in a peer-reviewed journal (Aesthetic Surgery Journal Open Forum) demonstrating efficacy for cellulite and skin laxity treatment. While this is a positive clinical validation event relevant to the company's product portfolio and market positioning, it does not fit neatly into the more specific event categories (not earnings, M\u0026A, litigation, impairment, etc.). The disclosure is material to investors assessing the company's clinical evidence base and competitive standing in aesthetic medicine, but the ambiguity about whether this constitutes a \"material\" event versus routine clinical publication reporting warrants moderate confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:00:20.648554+00:00","company_name":"Apyx Medical Corp","ticker":"APYX","filing_date":"2026-05-21"}]}